Myriad Genetics, Inc. (NASDAQ: MYGN) – Not A Clear Buying Opportunity?
The Vanguard Group, Inc. has recently announced that it has increased stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 0.09%. After grabbing 9.02 million shares, the institutional investor is now in possession of 7970.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 11.02% having worth around $140.56 million. Moreover, […]
